Roadmap to integrated Sepsis Prediction and Monitoring

SIQNATURETM is the molecular diagnostic solution for the early prediction and reliable monitoring of sepsis. With the announcement of this new integrated concept, SIRS-Lab paves the way to "decoding sepsis".

Unique Concept

Immune Monitoring
SIQNATURE is the first transcriptome-based immune-monitoring test and tracks a specific biomarker message closest to its insult. This ensures earliest information about the inflammation status.
Sepsis Score
Proprietary housekeeper genes have been defined in a large microarray study with more than 600 patients. By means of the housekeepers, an automated biostatistical analysis delivers the definite score which clarifies if the SIRS is either infectious or non-infectious.
Unique Immune Monitoring Concept

Clinical Benefit

Predictive Value
With a high predictive value for the transition from SIRS to sepsis, SIQNATURE delivers precise and reliable information complementary to current sepsis diagnostics.

Patient Outcome
In order to enable a meaningful impact on individual patient outcome, reliable biomarkers for the early observation of the inflammation status are urgently needed. SIQNATURETM has major potential to improve the early identification of patients at risk.
SIQNATURE clinical benefit

From Sample to Score

The biomarker information is directly taken from stabilized whole blood. After fluorescence PCR, SIRS-Lab's proprietary biostatistical transformation translates the multiple variables into one score.
SIQNATURE workflow

Dual Approach

Holistic Sepsis Diagnostics
SIRS-Lab's holistic diagnostic concept: combine the detection of microbial causes of infections and the monitoring of the host response within the critical time-frame of therapy. The integration of pathogen detection and host response monitoring is reflected in the “dual approach”.
Decoding Sepsis
SIQNATURETM is the milestone to fulfill this dual approach. In concert with the pathogen detection solution VYOO®, SIQNATURETM can significantly contribute to the de-escalation of antibiotic therapy in patients at risk.